abs74.txt	the	siu	(société	internationale	d'urologie)-icud	(international	consultation	onurologic	diseases)	working	group	on	systemic	therapy	for	metastatic	bladdercancer	has	summarized	most	recent	findings	aforementioned	topic	andcame	to	conclusions	and	recommendations	according	evidence	published		ineurope	united	states	treatment	uc	changed	a	greatdeal	recently	mainly	involving	move	from	chemotherapy	immune	checkpointblockers	this	is	particularly	true	in	platinum-refractory	disease	wheresupportive	randomized	data	exist	five	checkpoint	blockers	have	been	approved	inthis	setting	by	fda	avelumab	atezolizumab	durvalumab	nivolumab	andpembrolizumab	pembrolizumab
